Korro Bio (KRRO) Construction in Progress (2022 - 2024)

Korro Bio's (KRRO) quarterly Construction in Progress came in at $18.3 million in Q2 2024, up 36.57% on a QoQ basis from $13.4 million in Q1 2024.

Korro Bio (KRRO) Construction in Progress (2022 - 2024) Analysis & Trends

Korro Bio (KRRO) has 3 years of Construction in Progress data on file, last reported at $18.3 million in Q2 2024.

Quarterly Construction in Progress changed N/A year-over-year to $18.3 million in Q2 2024, while the trailing twelve-month figure through Jun 2024 was $18.3 million (changed N/A YoY) and the FY2023 annual result came in at $8.2 million, up 310.0% from the prior year.
Construction in Progress climbed to $18.3 million in Q2 2024, from $13.4 million in the prior quarter.
In the past five years, Construction in Progress ranged from a high of $18.3 million in Q2 2024 to a low of $2.0 million in Q4 2022.
A 3-year average of $10.5 million and a median of $10.8 million in 2024 frame the typical range for Construction in Progress.
The widest YoY moves for Construction in Progress: up 310.0% in 2023, down 310.0% in 2023.
Tracing KRRO's Construction in Progress over 3 years: stood at $2.0 million in 2022, then soared by 310.0% to $8.2 million in 2023, then soared by 123.17% to $18.3 million in 2024.
The last three Construction in Progress figures came in at $18.3 million (Q2 2024), $13.4 million (Q1 2024), and $8.2 million (Q4 2023), per Business Quant data.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Construction in Progress (Qtr)
1	Vertex Pharmaceuticals	137.11 Bn	129.26 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	84.98 Bn	76.99 Bn	3.93 Bn	-
3	Argenx Se	64.52 Bn	59.33 Bn	1.37 Bn	-
4	Moderna	53.23 Bn	48.09 Bn	52.00 Mn	-
5	BeOne Medicines	41.23 Bn	36.14 Bn	1.53 Bn	152.67 Mn
6	Alnylam Pharmaceuticals	30.65 Bn	27.34 Bn	992.69 Mn	-
7	Insmed	27.15 Bn	25.99 Bn	358.27 Mn	-
8	Royalty Pharma	26.98 Bn	26.14 Bn	-	-
9	BioNTech SE	26.78 Bn	8.39 Bn	668.28 Mn	-
10	Korro Bio	228.60 Mn	113.56 Mn	-	-

Download Data